Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;32(9):3911-5.

Complete pathologic response to neoadjuvant radiotherapy is predictive of oncological outcome in patients with soft tissue sarcoma

Dhruvil Shah  1 , Dariusz Borys, Steve R Martinez, Chin-Shang Li, Robert M Tamurian, Richard J Bold, Arta Monjazeb, Robert J Canter
Affiliations

Complete pathologic response to neoadjuvant radiotherapy is predictive of oncological outcome in patients with soft tissue sarcoma

Dhruvil Shah et al. Anticancer Res. 2012 Sep.

Abstract

We sought to determine if complete pathological necrosis (pathCR) predicts favorable oncological outcome in soft tissue sarcoma (STS) patients receiving pre-operative radiation monotherapy (RT).

Patients and methods: We evaluated 30 patients with primary STS treated with neoadjuvant RT followed by definitive resection, from 2000 to 2010 at our institution. We defined ≥ 95% tumor necrosis as pathCR.

Results: There were 22 STS of the extremities (73%), 7 of the retroperitoneum (23%), and 1 (4%) of the trunk. The median pathological percentage of tumor necrosis was 35% (range 5-100%) with three tumors (10%) demonstrating pathCR. With a median follow-up of 40 months, the 5-year local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and overall survival (OS) for the entire cohort were 100%, 61% ± 11%, and 69% ± 11%, respectively. Among patients with pathCR, 3-year DRFS was 100% compared to 63±11% in patients without pathCR (p=0.28).

Conclusion: Following neoadjuvant RT for STS, pathCR is associated with a clinically but not statistically significant 37% improvement in 3-year DRFS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan Meier curve depicting 5-year local recurrence-free survival, overall survival, and distant recurrence-free survival for the entire cohort of soft tissue sarcoma patients treated with preoperative radiotherapy following by resection with curative intent.
Figure 2
Figure 2
Kaplan Meier curve depicting distant recurrence-free survival grouped by presence or absence of near-complete pathologic necrosis in resected surgical specimen (≥ 95% tumor necrosis). Log-rank test P value is shown.
See this image and copyright information in PMC

References

    1. O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet. 2002;359:2235–2241. - PubMed
    1. Wunder JS, Nielsen TO, Maki RG, O’Sullivan B, Alman BA. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 2007;8:513–524. - PubMed
    1. Pisters PW, O’Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol. 2007;25:1003–1008. - PubMed
    1. Benjamin RS. SARC-CTOS imaging symposium: introduction to the problem from a clinical perspective. Oncologist. 2008;13 (Suppl 2):1–3. - PubMed
    1. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist. 2008;13 (Suppl 2):32–40. - PubMed

Publication types